Overview
Strategies to Control nOH: Clinician and Patient Perspectives
Clinician and Patient Perspectives: Text-Based Interviews
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Online, text-based interview activity which will include clinician and patient perspectives. The goal of this activity is to update clinicians on new and emerging science in the field of neurogenic orthostatic hypotension (nOH) to provide practicing clinicians with education on optimal use of new agents.
This activity is intended for neurologists, cardiologists and other clinicians involved in the management of patients with neurogenic orthostatic hypotension (nOH).
nOH is a disease that results from a combination of two factors. The most obvious one is a decrease in blood pressure (BP), either systolic (>20 mm Hg) or diastolic (>10 mm Hg) and can be observed and measured within the first three minutes of standing. The second factor contributing to nOH and which differentiates it from pure orthostatic hypotension is an impairment of the sympathetic nervous system resulting in the decreased release of norepinephrine from the postganglionic cells onto their targets (ie, blood vessels). Neurologists, cardiologists, and other clinicians who treat neurogenic orthostatic hypotension (nOH) need to be updated on issues that will lead to earlier diagnosis and appropriate treatment modalities. The goal of the interviews is to update clinicians on new and emerging science in the field of nOH to provide practicing clinicians with education on optimal use of new agents.
Upon completion of this activity, participants will be able to:
• Implement screening practices to assess patients for nOH.
• Utilize assessment tools in concert with physiologic measures to monitor changes in nOH and its impact on patient functioning.
• Explain the efficacy and risks associated with droxidopa compared with other therapies used to manage orthostatic hypotension.
• Formulate treatment plans considerate of patient comorbidities and multiple pharmacologic therapies.
• Implement screening practices to assess patients for nOH.
• Utilize assessment tools in concert with physiologic measures to monitor changes in nOH and its impact on patient functioning.
• Explain the efficacy and risks associated with droxidopa compared with other therapies used to manage orthostatic hypotension.
• Formulate treatment plans considerate of patient comorbidities and multiple pharmacologic therapies.
This activity is sponsored by ACHL.
This activity is supported by an educational grant from Lundbeck.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Robert Hauser, MD, MBA
Professor of Neurology, Molecular Pharmacology and Physiology
University of South Florida
Director, USF Health Byrd Parkinson’s Disease and Movement Disorders Center
University of South Florida
Tampa, FL
Professor of Neurology, Molecular Pharmacology and Physiology
University of South Florida
Director, USF Health Byrd Parkinson’s Disease and Movement Disorders Center
University of South Florida
Tampa, FL
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
Robert Hauser, MD, MBA (Faculty)
Consultant: Acorda Therapeutics, Adamas Pharmaceuticals, Back Bay Life Science Advisors, Biotie Therapies, Cynapsus Therapeutics, eResearch Technology, Inc., LifeMax, Lundbeck LLC, Neurocrine Biosciences, Neuropore Therapies, Pfizer, Inc., Pharma Two B, Ltd., Prexton Therapeutics, Sarepta Therapeutics, Sunovion Pharmaceuticals, Inc., Teva Pharmaceuticals, US WorldMeds.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: While it is a frequently cited nOH treatment option in the medical literature, use of fludrocortisone for the treatment of neurogenic orthostatic hypotension is considered off-label in the United States under current FDA-approved labeling.
The following financial relationships have been provided:
Consultant: Acorda Therapeutics, Adamas Pharmaceuticals, Back Bay Life Science Advisors, Biotie Therapies, Cynapsus Therapeutics, eResearch Technology, Inc., LifeMax, Lundbeck LLC, Neurocrine Biosciences, Neuropore Therapies, Pfizer, Inc., Pharma Two B, Ltd., Prexton Therapeutics, Sarepta Therapeutics, Sunovion Pharmaceuticals, Inc., Teva Pharmaceuticals, US WorldMeds.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: While it is a frequently cited nOH treatment option in the medical literature, use of fludrocortisone for the treatment of neurogenic orthostatic hypotension is considered off-label in the United States under current FDA-approved labeling.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pre-test, view the online newsletter and complete the post-test and evaluation. To receive credit, 60% must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact:
Liz Fortino, Program Coordinator
efortino@achlcme.org
773-714-0705 ext. 113
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this eNewsletter for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this eNewsletter for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.